David Wilfret

468 total citations
17 papers, 364 citations indexed

About

David Wilfret is a scholar working on Infectious Diseases, Epidemiology and Hepatology. According to data from OpenAlex, David Wilfret has authored 17 papers receiving a total of 364 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Infectious Diseases, 7 papers in Epidemiology and 4 papers in Hepatology. Recurrent topics in David Wilfret's work include Liver Disease Diagnosis and Treatment (4 papers), Hepatitis C virus research (4 papers) and HIV/AIDS drug development and treatment (4 papers). David Wilfret is often cited by papers focused on Liver Disease Diagnosis and Treatment (4 papers), Hepatitis C virus research (4 papers) and HIV/AIDS drug development and treatment (4 papers). David Wilfret collaborates with scholars based in United States, United Kingdom and Ireland. David Wilfret's co-authors include William Spreen, Shuguang Chen, Stephen C. Piscitelli, Elizabeth Gould, David M. Margolis, Susan L. Ford, Alan D. Hutson, Brigitta U. Mueller, Maureen M. Goodenow and John W. Sleasman and has published in prestigious journals such as Blood, Annals of Surgery and Antimicrobial Agents and Chemotherapy.

In The Last Decade

David Wilfret

17 papers receiving 355 citations

Peers

David Wilfret
Michelle L. Ray United States
Daryl S. Schiller United States
Paola Tatarelli Italy
James A. McDowell United States
Douglas Mangwanya Zimbabwe
Margherita Digaetano Italy
Vincent Madelain France
Laurence John United Kingdom
Héloïse Delagrèverie France
Nischal Ranganath United States
Michelle L. Ray United States
David Wilfret
Citations per year, relative to David Wilfret David Wilfret (= 1×) peers Michelle L. Ray

Countries citing papers authored by David Wilfret

Since Specialization
Citations

This map shows the geographic impact of David Wilfret's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Wilfret with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Wilfret more than expected).

Fields of papers citing papers by David Wilfret

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Wilfret. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Wilfret. The network helps show where David Wilfret may publish in the future.

Co-authorship network of co-authors of David Wilfret

This figure shows the co-authorship network connecting the top 25 collaborators of David Wilfret. A scholar is included among the top collaborators of David Wilfret based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Wilfret. David Wilfret is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Borroto–Esoda, Katyna, David Wilfret, Xiao Tong, et al.. (2024). SARS-CoV-2 viral dynamics in a placebo-controlled phase 2 study of patients infected with the SARS-CoV-2 Omicron variant and treated with pomotrelvir. Microbiology Spectrum. 12(2). e0298023–e0298023. 4 indexed citations
2.
Yang, Ziping, Nathalie Rioux, Hannah M. Jones, et al.. (2023). A comprehensive evaluation in clinic and physiologically‐based pharmacokinetic modeling and simulation to confirm lack of cytochrome P450–mediated drug–drug interaction potential for pomotrelvir. CPT Pharmacometrics & Systems Pharmacology. 12(10). 1553–1564. 3 indexed citations
3.
4.
5.
May, Addison K., Victor B. Talisa, David Wilfret, et al.. (2020). Estimating the Impact of Necrotizing Soft Tissue Infections in the United States: Incidence and Re-Admissions. Surgical Infections. 22(5). 509–515. 23 indexed citations
6.
Bulger, Eileen M., Addison K. May, Bryce R. H. Robinson, et al.. (2020). A Novel Immune Modulator for Patients With Necrotizing Soft Tissue Infections (NSTI). Annals of Surgery. 272(3). 469–478. 31 indexed citations
7.
Spreen, William, Susan L. Ford, Shuguang Chen, et al.. (2014). GSK1265744 Pharmacokinetics in Plasma and Tissue After Single-Dose Long-Acting Injectable Administration in Healthy Subjects. JAIDS Journal of Acquired Immune Deficiency Syndromes. 67(5). 481–486. 117 indexed citations
8.
Song, Ivy, Julie Borland, Shuguang Chen, et al.. (2014). Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir. European Journal of Clinical Pharmacology. 70(10). 1173–1179. 30 indexed citations
9.
10.
Adkison, Kimberly K., et al.. (2014). Effects of omeprazole and ritonavir on absorption and elimination of the hepatitis C virus NS5A inhibitor GSK2336805 in healthy adults. Clinical Pharmacology in Drug Development. 3(5). 338–345. 1 indexed citations
11.
Wilfret, David, Christian Voitenleitner, Mark Lovern, et al.. (2014). A randomized, double blind, dose escalation, first time in human study to assess the safety, tolerability, pharmacokinetics, and antiviral activity of single doses of GSK2485852 in chronically infected hepatitis C subjects. Clinical Pharmacology in Drug Development. 3(6). 439–448. 2 indexed citations
12.
Wilfret, David, et al.. (2013). Echocardiogram Study To Evaluate the Effect of the Novel Hepatitis C Virus NS5A Inhibitor GSK2336805 on Cardiac Contractility in Healthy Subjects. Antimicrobial Agents and Chemotherapy. 57(10). 5141–5143. 2 indexed citations
13.
Wilfret, David, Kimberly K. Adkison, Yu Lou, et al.. (2013). Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GSK2336805, an Inhibitor of Hepatitis C Virus (HCV) NS5A, in Healthy Subjects and Subjects Chronically Infected with HCV Genotype 1. Antimicrobial Agents and Chemotherapy. 57(10). 5037–5044. 21 indexed citations
14.
Wulff‐Burchfield, Elizabeth, Wiley A. Schell, Allen E. Eckhardt, et al.. (2010). Microfluidic platform versus conventional real-time polymerase chain reaction for the detection of Mycoplasma pneumoniae in respiratory specimens. Diagnostic Microbiology and Infectious Disease. 67(1). 22–29. 40 indexed citations
15.
16.
Wilfret, David, et al.. (2008). Epidemiology of Respiratory Syncytial Virus in Various Regions Within North Carolina During Multiple Seasons. North Carolina Medical Journal. 69(6). 447–452. 7 indexed citations
17.
Sleasman, John W., Robert P. Nelson, Maureen M. Goodenow, et al.. (1999). Immunoreconstitution after ritonavir therapy in children with human immunodeficiency virus infection involves multiple lymphocyte lineages. The Journal of Pediatrics. 134(5). 597–606. 64 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michelle L. Ray Breakdown of academic impact, for papers by Daryl S. Schiller Breakdown of academic impact, for papers by Paola Tatarelli Breakdown of academic impact, for papers by James A. McDowell Breakdown of academic impact, for papers by Douglas Mangwanya Breakdown of academic impact, for papers by Margherita Digaetano Breakdown of academic impact, for papers by Vincent Madelain Breakdown of academic impact, for papers by Laurence John Breakdown of academic impact, for papers by Héloïse Delagrèverie Breakdown of academic impact, for papers by Nischal Ranganath
Rankless by CCL
2026